Table 4.
Effect of ascorbic acid supplementation on H. pylori eradication
| Study | Regimen | AA dose mg/day | Duration (weeks) | Sample (n) | Eradication (%) | p value |
|---|---|---|---|---|---|---|
| Jarosz et al. [80] | Placebo | 0 | 4 | 24 | 0 | |
| Ascorbate | 5,000 | 4 | 27 | 29.6 | p=0.006 | |
| Zojaji et al. [81] | O,A,M,B | 0 | 2 | 162 | 48.8 | |
| O,A,M,B + ascorbate | 500 | 2 | 150 | 78 | p<0.0001 | |
| Sezikli et al. [82] | L,A,C,B | 0 | 2 | 80 | 60 | |
| L,A,C,B + ascorbate | 500 | 2 | 80 | 93.5 | p<0.005 | |
| Chuang et al. [83] | O,A,C250 | 0 | 1 | 55 | 68 | |
| O,A,C250 | 500 | 1 | 61 | 85 | p=0.03 | |
| O,A,C500 | 0 | 1 | 55 | |||
| Kaboli et al. [84] | O,A,C250 | 500 | 2 | 114 | 86.8 | p=0.623 |
| O,A,C500 | 0 | 2 | 100 | 89 | ||
| Kamiji et al. [85] (Protocol I) | Placebo | 0 | 4 | 17 | 0 | 0–15% (95% conf inter) |
| Ascorbate | 5000 | 4 | 21 | 0 | ||
| (Protocol II) [85] | Ascorbate | 5000 | 4 | 8 | 0 | |
| Chuang et al-metronidazole résistant [86] | L,A,M | 0 | 1 | 19 | 26.3 | P=NS |
| L,A,M + vitamin C,E | 500 | 7 | 23 | 21.7 | ||
| Chuang et al-metronidazole susceptible [86] | L,A,M | 0 | 1 | 30 | 80 | p=0.02 |
| L,A,M + vitamin C,E | 500 | 7 | 32 | 53.1 |
O = omeprazole, A = amoxicilllin, C = clarithromycin, B = Bismuth, L = lansoprazole, M = metronidazole